Physician profile
Stacy D Fisher
NPI 1518960939
$3,647.31
in general payments reported to CMS, 2019-2025
13 companies · $28.31 in 2025
The $28.31 reported for 2025 was less than what a typical Adult Congenital Heart Disease provider received nationally (typical 2025 total: $272).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $745 · 2021: $12.50 · 2022: $586 · 2023: $1,954 · 2024: $124 · 2025: $28.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,168 · Food and Beverage: $843 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,168.15 |
| Food and Beverage | $843.26 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,342.30 | 2021-2023 | Harmony, Mycarelink, Azure Xt Dr Mri Surescan |
| Actelion Pharmaceuticals, Ltd | $655.53 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $223.66 | 2019-2025 | Lifevest |
| Abbott Laboratories | $125.48 | 2022-2023 | Gallant |
| Actelion Pharmaceuticals US, INC. | $94.99 | 2024 | Opsumit, Uptravi |
| Pfizer INC. | $91.98 | 2019 | |
| Philips North America LLC | $50.55 | 2022-2024 | (5091) Amb Mon & Diag Und |
| Abiomed | $18.76 | 2023 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.08 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $13.89 | 2022 | |
| Novo Nordisk INC | $12.09 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.